Related Experiment Video

Updated: Jun 26, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

[Efficacy of memantine in Parkinson's disease with dementia]

O S Levin, L A Batukaeva

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |January 22, 2009
    PubMed

    Insights

    Memantine (M) effectively improved mental state in Parkinson's disease (PD) patients with dementia. This study demonstrated M's good tolerability and stable efficacy, comparable to Alzheimer's disease treatments.

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • Parkinson's disease (PD) often presents with dementia, posing significant treatment challenges.
    • Existing therapies for PD dementia have limitations, necessitating exploration of alternative treatments.

    Purpose of the Study:

    • To evaluate the efficacy and safety of memantine (M) in patients with Parkinson's disease (PD) and dementia.
    • To assess the impact of memantine on cognitive function, mental state, and quality of life in PD patients.

    Main Methods:

    • A clinical study involving 15 patients with PD and dementia treated with memantine.
    • Gradual dose escalation of memantine from 5 mg to 20 mg daily over four weeks.
    • Control group received no drug treatment.
    • Assessment using the Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Examination (MMSE), Clinical Global Impression (CGI) scale, neuropsychological tests, and the PDQ-8 quality of life scale.

    Main Results:

    • Memantine demonstrated a stable improvement in the mental state of patients with Parkinson's disease dementia.
    • The drug was well-tolerated by the study participants.
    • The efficacy observed in this study was comparable to that seen in memantine treatment for Alzheimer's disease.

    Conclusions:

    • Memantine is a potentially effective and well-tolerated treatment option for dementia associated with Parkinson's disease.
    • Further research is warranted to confirm these findings in larger patient cohorts.
    • Memantine may offer a valuable therapeutic strategy for managing cognitive decline in PD.

    Related Concept Videos

    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

    Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

    Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
    Dementia l: Introduction01:22

    Dementia l: Introduction

    Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
    Dementia01:30

    Dementia

    Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
    The progression of dementia is generally gradual.